AstraZeneca plans to invest over 3.6 million euro for Bulgarian clinical trials
AstraZeneca plans to invest over 3.6 million euro for Bulgarian clinical trials
Pharmaceuticals company AstraZeneca plans to invest over 7.0 million levs ($4.9 million/3.6 million euro) in clinical trials in Bulgaria this year, the executive director of its local unit said. “In 2014, the clinical trial program in Bulgaria comprises 25 active studies in all therapeutic areas in which AstraZeneca has a strong presence, including biologics,” Zoya Paunova told SeeNews in an interview.
According to IMS data cited by Paunova, AstraZeneca Bulgaria is growing faster than the wider market with a market share as of December 2013 of 4.74% in terms of value and 1.5% in terms of volume on the local prescription drug market.
Pin It
